UCB Pins Growth Hopes On Burgeoning Late-Stage Pipeline
Painful Skin Abscesses, Myasthenia Gravis And Refractory Epilepsy Targeted
UCB's R&D efforts include late-stage diverse but complementary immunologicals and anti-neuroinflammatories.
You may also be interested in...
Belgium’s UCB Pharma is expecting progress with new candidates for myasthenia gravis, psoriasis and osteoporosis this year.
UCB gets $120m up front from Roche for option rights to UCB0107 and retains full rights to the drug in progressive supranuclear palsy.
The Belgian group has a lot of catching up to do with Cosentyx and Taltz already well established but is confident bimekizumab’s mechanism of action, which neutralizes both IL-17A and IL-17F cytokines, offers an advantage over those two blockbusters.